Novartis’ Egaten (triclabendazole) Receives FDA’s Approval for Fascioliasis in the US

 Novartis’ Egaten (triclabendazole) Receives FDA’s Approval for Fascioliasis in the US

Novartis’ Egaten (triclabendazole) Receives FDA’s Approval for Fascioliasis in the US

Shots:

  • The approval is based on the study assessing Egaten (triclabendazole) in patients with fascioliasis aged ≥ 6yrs.
  • Novartis’ Egaten is in use since 2005 by WH, serving 2M fascioliasis patients in 30 countries, and renewed the agreement of donating Egaten in 2018 to 2022 for the treatment of 300,000 patients/year
  • Egaten (triclabendazole) is a drug targeted for fascioliasis, registered on WHO Model List of Essential Medicines and has received FDA’s Priority Review voucher based on this approval

Click here to read full press release/ article | Ref: Novartis | Image: Ophthalmology Innovation Summit

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post